What is the appropriate prescription for phentermine (dosage, quantity, duration, and sig) for a 50-year-old female patient with a BMI of 47.37?

Phentermine Prescription for 50-Year-Old Female with BMI 47.37

Start phentermine 15 mg orally once daily in the morning (approximately 2 hours after breakfast) for 12 weeks, dispensing 90 capsules with no refills, and ensure cardiovascular screening is completed before initiation.

Dosing Specifications

Rx: Phentermine HCl 15 mg capsules

• Sig: Take 1 capsule by mouth once daily in the morning (approximately 2 hours after breakfast)
• Quantity: 90 capsules
• Duration: 12 weeks (FDA-approved duration)
• Refills: 0 (Schedule IV controlled substance)

Rationale for Starting Dose

Start with 15 mg daily rather than the maximum 37.5 mg 1. This approach:

• Allows assessment of tolerability before escalation
• Minimizes cardiovascular and CNS side effects
• Follows FDA labeling that dosing should be individualized to obtain adequate response with the lowest effective dose 1

If the patient tolerates 15 mg well and needs additional appetite suppression after 2-4 weeks, you may increase to 30 mg daily (dispense 90 capsules of 30 mg for remaining duration).

Pre-Prescription Requirements

Mandatory Cardiovascular Screening

Before prescribing, you must exclude:

• History of cardiovascular disease (coronary artery disease, stroke, arrhythmias, heart failure)
• Uncontrolled hypertension
• Current blood pressure and heart rate measurement 2, 1

Phentermine is contraindicated in patients with cardiovascular disease 1. This patient's BMI of 47.37 places her at higher cardiovascular risk, making this screening critical.

Additional Contraindications to Rule Out

• Hyperthyroidism
• Glaucoma
• History of drug abuse
• Current or recent (within 14 days) MAOI use
• Pregnancy or breastfeeding
• Agitated states 1

Duration Considerations

The FDA approves phentermine for short-term use (12 weeks) 2, 1. However, the 2022 AGA guidelines acknowledge that "many practitioners use phentermine longer than 12 weeks in an off-label fashion" given obesity's chronic nature 2.

For initial prescription: Prescribe for 12 weeks as FDA-approved. If continuing beyond 12 weeks:

• Document specific benefits, tolerance, and lack of adverse effects
• Inform patient of off-label use and limited long-term data
• Verify state regulations regarding extended use 2
• Reassess every 3 months

Monitoring Requirements

Baseline

• Blood pressure and heart rate
• Weight and BMI
• Basic metabolic panel (if diabetic or on other medications)

Ongoing Monitoring

• Blood pressure and heart rate at each visit (especially first 12 weeks) 2
• Weight every 2-4 weeks
• Assess for adverse effects: insomnia, dry mouth, constipation, increased heart rate

Discontinuation Criteria

• New cardiovascular symptoms (dyspnea, angina, syncope, edema)
• Uncontrolled hypertension or tachycardia
• Intolerable side effects
• Lack of response (if <3% weight loss at 12 weeks, consider discontinuation or alternative therapy)

Critical Safety Warnings

Timing of Administration

Avoid late evening dosing due to insomnia risk 1. The 2-hour post-breakfast timing optimizes appetite suppression during high-risk eating periods while minimizing sleep disruption.

Cardiovascular Concerns

While phentermine increases norepinephrine (not serotonin like fenfluramine), cardiovascular caution remains essential 2. The 2022 AGA guidelines state phentermine "should be avoided in patients with a history of cardiovascular disease" 2. Blood pressure typically declines with weight loss, but heart rate may increase slightly 2.

Abuse Potential

Phentermine is Schedule IV controlled substance 2, 1. Prescribe the minimum quantity necessary and avoid early refills.

Drug Interactions

• Absolute contraindication: MAOIs (risk of hypertensive crisis) 1
• Caution with: Insulin/oral hypoglycemics (may need dose reduction), alcohol, other sympathomimetics 1

Lifestyle Modifications (Mandatory Adjunct)

Phentermine is indicated only as adjunct to comprehensive lifestyle intervention 1. The patient must engage in:

• Caloric restriction (structured meal plan)
• Regular physical activity
• Behavioral modification therapy

The AGA recommends phentermine "with lifestyle modifications, compared with lifestyle modifications alone" 2. Without lifestyle changes, medication efficacy is substantially reduced.

Expected Outcomes

Based on clinical trial data, expect:

• 3-month weight loss: Approximately 10-11 kg (10% total body weight) when combined with lifestyle intervention 3
• 12-month weight loss: Up to 15 kg with sustained use 3
• Mean weight loss of 6-7 kg over 12 weeks in monotherapy studies 4

Alternative Dosing Option

The FDA approved an 8 mg tablet formulation in 2016 for dosing up to 3 times daily (30 minutes before meals) 2. This allows:

• Lower individual doses (4-8 mg)
• Targeting high-risk eating periods
• "As needed" use before situations with hedonic food consumption

However, for initial prescription simplicity and compliance, the once-daily 15 mg approach is preferred.

Renal Impairment Consideration

This patient's renal function should be assessed. If severe renal impairment (eGFR 15-29 mL/min/1.73 m²), limit to 15 mg daily maximum 1. Avoid if eGFR <15 or on dialysis.